Genomic landscape of treatment refractory metastatic colorectal cancer

Keyphrases

• Metastatic Colorectal Cancer (mCRC) 100%
• Treatment Refractory 100%
• Genomic Landscape 100%
• Driver mutations 66%
• Tumor Tissue 50%
• Genome Sequencing 50%
• Treatment Options 33%
• Retrospective Analysis 33%
• Targeted Treatment 33%
• Next-generation Sequencing 33%
• Experimental Cancer Therapy 33%
• Consecutive Patients 16%
• Patient Demographics 16%
• Complex Disease 16%
• Phase II Trial 16%
• Oncology 16%
• Targeted Therapy 16%
• Genomic Signature 16%
• Herlev 16%
• Microsatellite Instability-high (MSI-H) 16%
• Personalized Treatment 16%
• Heterogeneous Disease 16%
• FDA-approved Drugs 16%
• Antineoplastic Drugs 16%
• Pathological Characteristics 16%
• Phase 1 Trial 16%
• Actionable Variants 16%
• Oncomine 16%
• Tumor mutational Burden 16%
• Matched Therapy 16%
• Characteristic Sequence 16%

Medicine and Dentistry

• Metastatic Colorectal Cancer 100%
• Malignant Neoplasm 66%
• Neoplasm 66%
• Targeted Therapy 50%
• Cancer Therapy 33%
• Genome Sequencing 33%
• Next Generation Sequencing 33%
• Experimental Neoplasm 33%
• Disease 16%
• Patient Population 16%
• Oncology 16%
• Microsatellite Instability 16%
• Genomic Signature 16%

Biochemistry, Genetics and Molecular Biology

• Genome Sequencing 100%
• Next Generation Sequencing 100%
• Microsatellite Instability 50%
• Genomic Signature 50%